All the news Showing 10 of 67 articles.Get an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Biktarvy combination pill may be most effective option for people with HIV and hepatitis B Liz Highleyman / 03 August 2022 Although two antiretroviral drug regimens proved about equally effective at suppressing HIV, the Biktarvy combination pill (bictegravir, emtricitabine and tenofovir alafenamide) did a better job suppressing hepatitis B virus (HBV) ... Hepatitis B treatment for all who need it an "achievable public health goal" for Malawi Keith Alcorn / 13 December 2021 Providing hepatitis B treatment for everyone who needs it in Malawi is an achievable public health goal, researchers from the Malawi-Liverpool-Wellcome Trust programme report, following community surveys in Blantyre, Malawi. Hepatitis B treatment ... People with HIV and hepatitis B should have ongoing monitoring for liver cancer Liz Highleyman / 15 March 2021 People with HIV and hepatitis B co-infection remain at risk for developing hepatocellular carcinoma (HCC) despite antiviral treatment and should undergo regular monitoring for liver cancer, according to research presented ... 2.5 million people in Africa need urgent hepatitis B treatment Keith Alcorn / 09 December 2020 Around 2.5 million people with hepatitis B in sub-Saharan Africa already have cirrhosis and need immediate antiviral treatment, a systematic review of published studies reports this month in the journal Liver International. Approximately ... Some hepatitis B patients can safely stop antivirals Liz Highleyman / 24 November 2020 Many people who take nucleoside/nucleotide antivirals for chronic hepatitis B can safely discontinue treatment, although this usually does not lead to a cure, researchers reported last week at the AASLD virtual Liver Meeting. Nucleoside/nucleotide analogues such ... Stopping antivirals may offer a chance for a hepatitis B cure Liz Highleyman / 06 September 2020 Discontinuation of long-term nucleoside/nucleotide antiviral treatment for hepatitis B can allow some people to achieve a cure, according to a pair of presentations last week at the 2020 Digital International Liver Congress. This may happen ... Hepatitis B treatment suboptimal in people with HIV in Africa Keith Alcorn / 04 February 2020 Testing for chronic hepatitis B infection was very low in people living with HIV in Cameroon, a country with a high burden of hepatitis B, and suppression of hepatitis B virus was ... Hepatitis B antiviral drugs reduce liver cancer risk Liz Highleyman / 19 November 2019 Treating hepatitis B virus (HBV) with nucleoside/nucleotide antiviral drugs was associated with a lower risk of developing hepatocellular carcinoma (HCC), the most common type of liver cancer, according to studies presented last week ... FDA warns of rare cases of serious liver injury with newer hepatitis C drugs Keith Alcorn / 29 August 2019 The US Food and Drug Administration (FDA) has issued a warning about the risk of serious liver injury in people with hepatitis C after starting recently approved direct-acting antiviral regimens that contain ... Tenofovir may lower the risk of liver cancer more than entecavir Liz Highleyman / 18 April 2019 People with hepatitis B who were treated with tenofovir disoproxil fumarate (TDF; Viread) were less likely to develop hepatocellular carcinoma (HCC) than those treated with entecavir (Baraclude) in a large observational study, according ... ← First12345...7Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive